Study finds potential type 2 diabetes aid in Takeda's drug

06/29/2011 | San Francisco Chronicle

A study presented at the annual meeting of the American Diabetes Association found that Takeda Pharmaceutical's TAK-875 drug fared better in reducing the risk of hypoglycemia in patients with type 2 diabetes compared to those in glimepiride and placebo treatments. It was just as effective as glimepiride in lowering hemoglobin A1c.

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Director of Litigation
Center for Science in the Public Interest
Washington, DC
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC